1-Boc-4-(4-羟基苯基)-哌嗪 | 158985-25-2

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物 - 羧酸酯及其衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-Boc-4-(4-羟基苯基)-哌嗪
• 中文别名: 1-BOC-4-(4-羟基苯基)-哌嗪
• 英文名称: tert-butyl 4-(4-hydroxyphenyl)piperazine-1-carboxylate
• 英文别名: tert-butyloxy-N-(4-(4-hydroxyphenyl)piperazin-1-yl)formamide；4-boc-1-(4-hydroxyphenyl)piperazine；4-(4-Hydroxyphenyl)piperazine-1-carboxylic acid tert-butyl ester
• CAS: 158985-25-2
• 化学式: C₁₅H₂₂N₂O₃
• 分子量: 278.351
• InChiKey: YEHWSWXESXPBOS-UHFFFAOYSA-N

物化性质

• 沸点：
  436.0±40.0 °C(Predicted)
• 密度：
  1.167±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  53
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933599090
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Boc-4-(4-hydroxy-phenyl)-piperazine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Boc-4-(4-hydroxy-phenyl)-piperazine
CAS number: 158985-25-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C15H22N2O3
Molecular weight: 278.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  1-Boc-4-(4-溴苯基)哌嗪	tert-butyl 4-(4-bromophenyl)piperazine-1-carboxylate	352437-09-3	C15H21BrN2O2	341.248
  ——	tert-butyl 4-(4-benzyloxyphenyl)piperazine-1-carboxylate	943035-30-1	C22H28N2O3	368.476
  4-[4-(N-BOC)哌嗪-1-基]苯基硼酸频哪酯	tert-butyl 4-[4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate	470478-90-1	C21H33BN2O4	388.315
  1-对羟基苯基哌嗪	1-(4-hydroxyphenyl)piperazine	56621-48-8	C10H14N2O	178.234

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  1-(3-羟基苯基)-哌嗪-4-羧酸叔丁酯	tert-butyl 4-(3-hydroxyphenyl)piperazine-1-carboxylate	198627-86-0	C15H22N2O3	278.351
  ——	tert-butyl 4-(4-(2-fluoroethoxy)phenyl)piperazine-1-carboxylate	913734-71-1	C17H25FN2O3	324.396
  ——	Tert-butyl 4-[4-(2-methylpropoxy)phenyl]piperazine-1-carboxylate	1247040-88-5	C19H30N2O3	334.459
  ——	4-[4-(3-chloro-propoxy)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester	398473-97-7	C18H27ClN2O3	354.877
  ——	tert-butyl 4-(4-(2-(dimethylamino)ethoxy)phenyl)piperazine-1-carboxylate	479225-81-5	C19H31N3O3	349.473
  ——	tert-butyl 4-(4-(octyloxy)phenyl)piperazine-1-carboxylate	179162-41-5	C23H38N2O3	390.566
  ——	1-(tert-butyloxycarbonyl)-4-(4-methoxycarbonylmethyloxyphenyl)piperazine	198627-46-2	C18H26N2O5	350.415
  ——	tert-butyl 4-(4-benzyloxyphenyl)piperazine-1-carboxylate	943035-30-1	C22H28N2O3	368.476
  4-(3-甲酰基-4-羟基苯基)哌嗪-1-羧酸叔丁酯	tert-butyl 4-(3-formyl-4-hydroxyphenyl)piperazine-1-carboxylate	343306-50-3	C16H22N2O4	306.362
  ——	Tert-butyl 4-[4-[[4-(trifluoromethyl)phenyl]methoxy]phenyl]piperazine-1-carboxylate	1163268-99-2	C23H27F3N2O3	436.474

反应信息

• 作为反应物：
  描述：

  1-Boc-4-(4-羟基苯基)-哌嗪 在 盐酸 、 aluminum (III) chloride 、 水 、 sodium carbonate 、 potassium hydrogencarbonate 、 N,N-二异丙基乙胺 、 sodium iodide 作用下， 以 异丙醚 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 47.5h， 生成 维拉佐酮
  参考文献：
  名称：

  一种维拉唑酮中间体的制备方法及中间体

  摘要：

  本发明公开了一种维拉唑酮中间体的制备方法及中间体。本发明的维拉唑酮中间体5-哌嗪基苯并呋喃-2-甲酰亚胺盐的制备方法，其包含下列步骤：将如式7所示化合物在无机强酸的水溶液中，进行如下所示的水解脱保护成盐反应；其中，X为无机强酸；所述的无机强酸为盐酸、硫酸或氢溴酸。本发明还公开了如式7所示化合物和如式6所示化合物及其制备方法。本发明的制备方法收率高，易纯化，纯度高，成本低，适合工业化大生产。

  公开号：

  CN104211668B
• 作为产物：
  描述：

  1-Boc-4-(4-溴苯基)哌嗪 在 sodium peroxoborate tetrahydrate 、 potassium acetate 、 palladium diacetate 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 32.0h， 生成 1-Boc-4-(4-羟基苯基)-哌嗪
  参考文献：
  名称：

  Use of Small-Molecule Crystal Structures To Address Solubility in a Novel Series of G Protein Coupled Receptor 119 Agonists: Optimization of a Lead and in Vivo Evaluation

  摘要：

  G protein coupled receptor 119 (GPR119) is viewed as an attractive target for the treatment of type 2 diabetes and other elements of the metabolic syndrome. During a program toward discovering agonists of GPR119, we herein describe optimization of an initial lead compound, 2, into a development candidate, 42. A key challenge in this program of work was the insolubility of the lead compound. Small-molecule crystallography was utilized to understand the intermolecular interactions in the solid state and resulted in a switch from an aryl sulphone to a 3-cyanopyridyl motif. The compound was shown to be effective in wild-type but not knockout animals, confirming that the biological effects were due to GPR119 agonism.

  DOI：

  10.1021/jm300310c

文献信息

• [EN] ANTHELMINTIC AGENTS AND THEIR USE<br/>[FR] AGENTS ANTHELMINTIQUES ET LEUR UTILISATION
  申请人：INTERVET INT BV

  公开号：WO2010115688A1

  公开（公告）日：2010-10-14

  This invention is directed to compounds and salts that are generally useful as anthelmintic agents or as intermediates in processes for making anthelmintic agents. This invention also is directed to processes for making the compounds and salts, pharmaceutical compositions and kits comprising the compounds and salts, uses of the compounds and salts to make medicaments, and treatments comprising the administration of the compounds and salts to animals in need of the treatments.

  这项发明涉及一般用作驱虫剂或作为制备驱虫剂的中间体的化合物和盐。这项发明还涉及制备这些化合物和盐的方法，包括这些化合物和盐的药物组合物和试剂盒，使用这些化合物和盐制备药物，以及将这些化合物和盐用于需要治疗的动物的治疗方法。
• [EN] SUBSTITUTED PIPERAZINES, (1,4) DIASZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS<br/>[FR] PIPERAZINES, (1,4) DIAZEPINES, ET 2,5-DIAZABICYCLO (2.2.1) HEPTANES SUBSTITUES EN TANT QU'ANTAGONISTES DE L'HISTAMINE H1 ET/OU H3 OU ANTAGONISTES INVERSES DE L'HISTAMINE H3
  申请人：GLAXO GROUP LTD

  公开号：WO2004035556A1

  公开（公告）日：2004-04-29

  The present invention relates to novel piperazine and azepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurodegenerative disorders including Alzheimer's disease.

  本发明涉及具有药理活性的新型哌嗪和氮杂七元环衍生物，其制备方法，含有它们的组合物以及它们在治疗包括阿尔茨海默病在内的神经退行性疾病中的应用。
• [EN] SUBSTITUTED PIPERAZINE COMPOUNDS AND METHODS AND USE THEREOF<br/>[FR] COMPOSÉS PIPÉRAZINIQUES SUBSTITUÉS, PROCÉDÉS ET UTILISATION ASSOCIÉS
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2015169180A1

  公开（公告）日：2015-11-12

  Provided herein are novel piperazine compounds acting as selective serotonin reuptake inhibitors and/or the 5-HT1A receptor agonists. The invention also relates to the methods of preparing the compound and pharmaceutical composition, and the use of treating central nervous system dysfunction in mammals especially in humans.

  本文提供了作为选择性血清素再摄取抑制剂和/或5-HT1A受体激动剂的新型哌嗪化合物。该发明还涉及制备该化合物和药物组合物的方法，以及用于治疗哺乳动物中枢神经系统功能障碍，特别是人类的用途。
• [EN] 2-AMINO-4-HYDROXY-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF T CELL ACTIVATION FOR THE TREATMENT OF INFLAMMATORY DISEASES<br/>[FR] DERIVES DE 2-AMINO-4-HYDROXY-5-PYRIMIDINOCARBOXAMIDE ET COMPOSES ASSOCIES SERVANT D'INHIBITEURS DE L'ACTIVATION DES LYMPHOCYTES T POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES
  申请人：AMGEN INC

  公开号：WO2005009443A1

  公开（公告）日：2005-02-03

  The present invention relates to pyrimidine or pyridine carboxamides or pharmaceutically-acceptable salts thereof. Also included is a method of treatment of inflammation, inhibition of T cell activation and proliferation, arthritis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, organ transplant, acute transplant or heterograft or homograft rejection, transplantation tolerance induction, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, including ulcerative colitis, Crohn's disease, lupus, contact hypersensitivity, delayed-type hypersensitivity, and gluten-sensitive enteropathy, type 1 diabetes, psoriasis, contact dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune polyglandular disease, autoimmune alopecia, pernicious anemia, vitiligo, autoimmune hypopituatarism, Guillain-Barre syndrome, glomerulonephritis, serum sickness, uticaria, allergic diseases, asthma, hayfever, allergic rhinitis, scleracielma, mycosis fungoides, dermatomyositis, alopecia areata, chronic actinic dermatitis, eczema, Behcet's disease, Pustulosis palmoplanteris, Pyoderma gangrenum, Sezary's syndrome, atopic dermatitis, systemic schlerosis, morphea, atopic dermatitis, colon carcinoma or thymoma in a mammal comprising administering a therapeutically-effective amount a compound as described above.

  本发明涉及嘧啶或吡啶甲酰胺或其药用可接受的盐。还包括一种治疗炎症、抑制T细胞激活和增殖、关节炎、类风湿性关节炎、银屑病关节炎、骨关节炎、器官移植、急性移植或异体移植或同种异体移植排斥、移植耐受性诱导、缺血或再灌注损伤、心肌梗死、中风、多发性硬化症、炎症性肠病，包括溃疡性结肠炎、克罗恩病、狼疮、接触超敏反应、迟发型超敏反应和谷蛋白敏感性肠病、1型糖尿病、银屑病、接触性皮炎、桥本甲状腺炎、舍格伦综合征、自身免疫性甲状腺功能亢进、阿狄森病、自身免疫多腺体病、自身免疫性脱发、恶性贫血、白癜风、自身免疫性垂体功能减退、吉兰-巴雷综合征、肾小球肾炎、血清病、荨麻疹、过敏性疾病、哮喘、花粉症、过敏性鼻炎、硬皮病、真菌病、皮肌炎、斑秃、慢性日光性皮炎、湿疹、贝赫切特病、掌跖脓疱病、脓皮病、塞扎里综合征、特应性皮炎、系统性硬化病、硬皮病、特应性皮炎、结肠癌或胸腺瘤的方法，包括施用如上所述的化合物的治疗有效量。
• 신규한 바이사이클릭 니트로이미다졸 카바메이트 화합물, 이를 제조하는 방법 및 이를 유효성분으로 함유하는 결핵 질환의 예방 또는 치료용 약제학적 조성물
  申请人：KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY 한국화학연구원(319980077651)

  公开号：KR101564425B1

  公开（公告）日：2015-10-30

  본 발명은 하기 화학식 1로 표시되는 바이사이클릭 니트로이미다졸 카바메이트 화합물, 이의 광학이성질체 또는 이의 약학적으로 허용가능한 염, 이를 제조하는 방법 및 이를 유효성분으로 함유하는 결핵 질환의 예방 또는 치료용 약제학적 조성물에 관한 것이다. [화학식 1] 상기 화학식 1에서, R1 및 R2는 각각 발명의 상세한 설명에서 정의한 바와 같다. 본 발명의 바이사이클릭 니트로이미다졸 카바메이트 화합물은 활동성 및 비활동성 결핵균에 대해 우수한 억제 효과를 나타내므로, 결핵의 치료에 유용하게 사용될 수 있다.

  本发明涉及如下化学式1所示的生物合成硝基咪唑啉酮卡巴梅特化合物、其光学异构体或其药学上可接受的盐，其制备方法及包含其作为有效成分的用于预防或治疗结核病的药物组合物。在化学式1中，R1和R2分别如发明详细说明中定义。本发明的生物合成硝基咪唑啉酮卡巴梅特化合物对活性和非活性结核菌表现出优异的抑制效果，因此可以有效地用于结核病治疗。